Updated treatment for influenza A and B

Area of Science:

• Virology
• Public Health
• Infectious Diseases

Background:

• Influenza significantly impacts public health, causing widespread illness, mortality, and substantial healthcare costs.
• Vaccination remains the primary strategy for influenza prevention.
• Antiviral medications serve as crucial adjuncts for managing influenza outbreaks.

Purpose of the Study:

• To review the role of antiviral agents in influenza prevention and treatment.
• To discuss the efficacy and appropriate use of older and newer antiviral medications.
• To highlight the importance of early diagnosis and timely intervention in influenza management.

Main Methods:

• Literature review of existing studies on influenza antivirals.
• Analysis of the efficacy of amantadine, rimantadine, zanamivir, and oseltamivir.
• Evaluation of treatment timing and impact on symptom duration and severity.

Main Results:

• Antiviral agents reduce illness duration by 1-2.5 days and alleviate some symptoms.
• Amantadine and rimantadine are effective against influenza A, particularly when it's the predominant strain.
• Zanamivir and oseltamivir are indicated for both influenza A and B.
• Optimal effectiveness requires administration within 48 hours of symptom onset.

Conclusions:

• Early presentation of symptoms and rapid diagnosis by physicians are essential for effective antiviral therapy.
• Further research is needed on antiviral resistance and use in specific populations (geriatric, high-risk, pediatric).
• Antiviral agents are valuable tools in combating influenza morbidity and mortality when used appropriately.